Pulmonary Vascular Versus Right Ventricular Function Changes During Targeted Therapies of Pulmonary Hypertension.

The article focuses on a study which looks into the relationship between pulmonary vascular resistance (PVR) and right ventricular ejection fraction (RVEF) in patients with pulmonary hypertension (PH). The study has discovered changes in the right ventricular function and hypertensive pulmonary circulation during the pulmonary hypertension's targeted therapies. It has compared the combination therapy with epoprostenol and bosentan and epoprostenol monotherapy. However, it has also identified that the preservation of PVR is not guaranteed by a small PVR reduction.